TERT Promoter Mutations in Papillary Thyroid Microcarcinomas

Thyroid

Volumn 25, Issue 9, 2015, Pages 1013-1019

  De Biase, Dario ^a   Gandolfi, Greta ^b   Ragazzi, Moira ^b   Eszlinger, Markus ^c   Sancisi, Valentina ^b   Gugnoni, Mila ^b   Visani, Michela ^a   Pession, Annalisa ^a   Casadei, Gianpaolo ^d   Durante, Cosimo ^e   Costante, Giuseppe ^f   Bruno, Rocco ^g   Torlontano, Massimo ^h   Paschke, Ralf ^c   Filetti, Sebastiano ^e   Piana, Simonetta ^b   Frasoldati, Andrea ^b   Tallini, Giovanni ^a   Ciarrocchi, Alessia ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Azienda USL di Bologna   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^g Tinchi Pisticci Hospital   (Italy)

^h CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROMOTER REGION; THYROID CARCINOMA; ALLELE; BIOLOGY; CARCINOMA, PAPILLARY; CLINICAL TRIAL; COHORT ANALYSIS; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; INCIDENCE; ITALY; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PROGNOSIS; THYROID NEOPLASMS;

ADULT; ALLELES; CARCINOMA, PAPILLARY; COHORT STUDIES; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TELOMERASE; THYROID NEOPLASMS;

EID: 84940665104     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0101     Document Type: Article

References (28)

1. Davies L, Welch HG 2014 Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317-322
2. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R 2013 Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:965212
3. Mehanna H, Al-Maqbili T, Carter B, Martin E, Campain N, Watkinson J, McCabe C, Boelaert K, Franklyn JA 2014 Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J Clin Endocrinol Metab 99:2834-2843
4. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K, Miya A 2010 An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 34:28-35
5. Ahn HS, Kim HJ, Welch HG 2014 Korea's thyroid-cancer ''epidemic''-screening and overdiagnosis. New Engl J Med 371:1765-1767
6. Lee JH, Shin SW 2014 Overdiagnosis and screening for thyroid cancer in Korea. Lancet 384:1848
7. Piana S, Ragazzi M, Tallini G, de Biase D, Ciarrocchi A, Frasoldati A, Rosai J 2013 Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis. Hum Pathol 44:556-565
8. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, Filetti S, Group PTCS 2013 Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab 98:636-642
9. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA 2013 Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-959
10. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H 2013 TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021-6026
11. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J 2013 High frequency of telomerase reversetranscriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218
12. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P 2013 Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185
13. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R 2013 TERT promoter mutations in familial and sporadic melanoma. Science 339:959-961
14. Huang DS, Wang Z, He XJ, Diplas BH, Yang R, Killela PJ, Meng Q, Ye ZY, Wang W, Jiang XT, Xu L, He XL, Zhao ZS, Xu WJ, Wang HJ, Ma YY, Xia YJ, Li L, Zhang RX, Jin T, Zhao ZK, Xu J, Yu S, Wu F, Liang J, Wang S, Jiao Y, Yan H, Tao HQ 2015 Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-976
15. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V 2015 TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol 172:403-413
16. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA 2013 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-1566
17. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M 2013 Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20:603-610
18. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M 2014 TERT promoter mutations and their association with BRAFV600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99:E1130-1136
19. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Maximo V, Sobrinho-Simoes M, Soares P 2014 TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99:E754-765
20. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J 2014 BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32:2718-2726
21. De Lellis RA, Lloyd RV, Heitz PU, Eng C (Eds) 2004 World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Endocrine Organs. IARC Press, Lyon, France
22. Edge SB Byrd D, Compton CC, Fritz AG, Greene FL, Trotti A 2010 AJCC Cancer Staging Manual. Seventh edition. Springer, New York, NY
23. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A 2012 BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 97:E1745-1749
24. de Biase D, Cesari V, Visani M, Casadei GP, Cremonini N, Gandolfi G, Sancisi V, Ragazzi M, Pession A, Ciarrocchi A, Tallini G 2014 High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. J Clin Endocrinol Metab 99:E1530-1538
25. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, Filetti S, Papillary Thyroid Cancer Study G 2010 Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 95:4882-4888
26. Li C, Lee KC, Schneider EB, Zeiger MA 2012 BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97:4559-4570
27. Li F, Chen G, Sheng C, Aaron GM, Huang Y, Lv Z, Xu H, Xing M, Qu S 2015 BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer 22:159-168
28. Wartofsky L 2013 Should patients with papillary microcarcinoma undergo radioiodine ablation? Endocrine 44:278-279